title: 68Ga-DOTATATE PET/CT in Nonneuroendocrine Tumors: A Pictorial Essay.
abstract: PET-CT with somatostatin analogs labeled with Ga is increasingly recognized as the best imaging modality for the evaluation of well-differentiated neuroendocrine tumors (NETs). However, somatostatin receptor (SSR) is not an exclusive marker for NET. A variety of tumors other than NETs express SSR, leading to a significant risk of false-positive PET/CT results. We illustrate false-positive Ga-DOTATATE PET/CT findings due to high uptake by non-Hodgkin lymphoma, metastatic meningioma, breast cancer, thyroid adenoma, and papillary carcinoma. Although Ga-DOTATATE is a noteworthy tracer for oncological application, pathological conditions with overexpression of SSR should be recognized to prevent misinterpretation of PET/CT images.
authors.affiliation: From the Imaging Department, Hospital Israelita Albert Einstein, São Paulo, Brazil.
authors.forename: Lilian Yuri Itaya
authors.initials: LYI
authors.lastname: Yamaga
authors.forename: Jairo
authors.initials: J
authors.lastname: Wagner
authors.forename: Marcelo Buarque de Gusmão
authors.initials: MBG
authors.lastname: Funari
mesh_terms: D000328:Adult; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018358:Neuroendocrine Tumors / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000473:pathology; D009942:Organometallic Compounds; D000072078:Positron Emission Tomography Computed Tomography; D017481:Receptors, Somatostatin / Q000378:metabolism
chemical_list: D009942:Organometallic Compounds; D017481:Receptors, Somatostatin; C513399:gallium Ga 68 dotatate